|
ETNA (Evaluating Treatment with Neoadjuvant Abraxane) randomized phase III study comparing neoadjuvant nab-paclitaxel (nab-P) versus paclitaxel (P) both followed by anthracycline regimens in women with HER2-negative high-risk breast cancer: A MICHELANGO study. |
|
|
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Celgene; Genomic Health; GlaxoSmithKline; Merck Sharp & Dohme; Pfizer; Roche; Synaffix; Synthon; Taiho Pharmaceutical; Tiziana Life Sciences |
Patents, Royalties, Other Intellectual Property - Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Novartis; Pfizer; Roche/Genentech |
Research Funding - Lilly; Novartis; Roche |
Travel, Accommodations, Expenses - AstraZeneca; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Pfizer; Roche |
Travel, Accommodations, Expenses - Amgen |
|
|
Research Funding - Celgene |
|
|
Consulting or Advisory Role - Genentech/Roche; Roche |
Travel, Accommodations, Expenses - Eisai; Roche |
|
|
|
|
|
Consulting or Advisory Role - Celgene |
|
|
Consulting or Advisory Role - Amgen; Celgene |